Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081492 | 0.85 | MAPT (0.47) | LMNAKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL6081150 | 0.84 | TP53 (0.43) | LMNAKMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL6410131 | 0.81 | LMNA (0.60) | LMNAKMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL10192221 | 0.73 | POLA1 (0.76) | KMT2AALDH1A1MEN1KDM4EPOLA1 | |
| SCHEMBL14071853 | 0.73 | POLA1 (0.58) | LMNAKMT2AALDH1A1MEN1HSD17B10 | |
| SCHEMBL5143836 | 0.71 | ALDH1A1 (0.63) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL18617342 | 0.70 | ALDH1A1 (0.64) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL5144131 | 0.69 | ALDH1A1 (0.63) | LMNAKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL10259764 | 0.69 | LMNA (0.61) | LMNAALDH1A1HSD17B10KDM4EMAPT | |
| SCHEMBL8305649 | 0.69 | HTT (0.61) | LMNAKMT2AALDH1A1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | claimed |
| EP-1602368-A2 | Cdc25 phosphatase inhibitors | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2005-12-07 | — | — | EP | claimed |
| JP-2004506618-A | — | — | 2004-03-04 | — | — | JP | claimed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | claimed |
| EP-1370255-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-12-17 | — | — | EP | claimed |
| WO-2002009686-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2002-02-07 | — | — | WO | claimed |
| EP-2335702-A1 | Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent | IPSEN PHARMA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES | 2009-10-08 | — | — | US | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| EP-1792905-A1 | Product containing at least one phosphatase CDC25 inhibitor combined with at least one other anticancer agent | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-7196084-B2 | Cdc25 phosphatase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | disclosed |
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | SCRAS | 2006-07-13 | — | — | US | disclosed |
| EP-1641453-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| EP-1602368-A2 | Cdc25 phosphatase inhibitors | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005000852-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1370255-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002009686-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034103-A1 | Cdc25 photophatase inhibitors | CDC25C, CDC25A, CDC25B | LMNA 4398/4885KMT2A 2705/4885ALDH1A1 3103/4885 |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | LMNA 2565/4885KMT2A 1598/4885ALDH1A1 2847/4885 |
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | CDC25A, CDC25C, CDC25B | LMNA 4249/4885KMT2A 1728/4885ALDH1A1 1528/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | LMNA 2582/4885KMT2A 1461/4885ALDH1A1 2313/4885 |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | CDC25A, CDC25C, CDC25B | LMNA 4249/4885KMT2A 1728/4885ALDH1A1 1528/4885 |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | CDC25A, CDC25C, CDC25B | LMNA 2552/4885KMT2A 1292/4885ALDH1A1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.